 |
인쇄하기
취소
|
Pharmaceutical companies fare well with generic drugs
Korea’s leading drugmakers saw their flagship generic products’ sales increasing due to robust demand last year, while the revenues in homegrown drugs were still discouraging.
According to Ubist market data, Hanmi Pharmaceutical recorded 41.3 billion won from last year’s sales of Amosartan, followed by Daewoong’s Albis with 40 billion won and Dong-A’s Orodipine with 21.6 billion won.
Mark...
According to Ubist market data, Hanmi Pharmaceutical recorded 41.3 billion won from last year’s sales of Amosartan, followed by Daewoong’s Albis with 40 billion won and Dong-A’s Orodipine with 21.6 billion won.
Mark...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.